SLCO1B1 rs4148211: Understanding Statin Response and Genetics
The rs4148211 variant is a genetic marker located within the SLCO1B1 gene, which plays a critical role in how the liver processes certain medications. Research has investigated this gene's influence on the transport of statins, which are commonly prescribed drugs used to manage cholesterol levels.
What each genotype means
Normal transporter function
This genotype is associated with normal function of the OATP1B1 transporter protein, which helps the liver process certain medications. Research indicates that individuals with this genotype typically have a lower risk of statin-associated muscle symptoms compared to those carrying the C allele. Please discuss your medication options and any potential side effects with your clinician or pharmacist.
This is the most common genotype in most global populations.
Intermediate transporter function
This genotype is associated with intermediate activity of the OATP1B1 transporter, which can lead to higher levels of certain statins in your bloodstream. You may have a moderately increased risk of experiencing muscle-related side effects when taking specific statins compared to those with the TT genotype. Please consult your healthcare provider or pharmacist to discuss whether your current medication dosage is appropriate for your genetic profile.
This genotype is found in a significant portion of the population, with frequencies varying by ancestry.
Reduced transporter function
This genotype is associated with significantly reduced activity of the OATP1B1 transporter, which can lead to higher systemic exposure to certain statins. Research indicates that individuals with this genotype have a higher risk of developing statin-induced myopathy, sometimes referred to in clinical literature as being associated with the *5 or *15 star alleles. It is important to discuss your medication therapy and potential dosage adjustments with your clinician or pharmacist to ensure your treatment is safe and effective.
This genotype is less common than the TT or TC genotypes and its frequency varies significantly across different ethnic and ancestral groups.
What is the rs4148211 Variant?
The rs4148211 variant is a single nucleotide polymorphism (SNP) situated within the SLCO1B1 gene on chromosome 12. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is often studied alongside other markers in the same gene, such as the well-characterized rs4149056, which is known to influence the function of the OATP1B1 transporter protein. While rs4148211 is located in a region associated with the regulation of this transporter, it is important to distinguish it from the primary functional variants that have been more extensively linked to clinical outcomes. Researchers monitor these markers to understand how subtle differences in our genetic code can lead to variations in how our bodies interact with pharmaceutical compounds. Because genes often work in clusters, rs4148211 is frequently analyzed as part of a broader genetic landscape that helps scientists map out the complex relationship between inherited DNA and drug metabolism.
The Role of the SLCO1B1 Gene
The SLCO1B1 gene provides instructions for making a protein called organic anion transporting polypeptide 1B1 (OATP1B1). This protein is primarily found in the liver, where it acts as a gatekeeper, facilitating the uptake of various substances from the blood into liver cells. This process is essential for the metabolism and eventual clearance of many drugs, including statins, which are widely used to lower cholesterol. When the OATP1B1 transporter functions optimally, it helps maintain appropriate levels of these medications in the bloodstream. However, if the transporter's efficiency is altered due to genetic variations, the concentration of the drug in the blood may increase. Higher-than-expected levels of statins in the circulation are hypothesized to be a contributing factor to muscle-related side effects, known as myopathy. By studying the SLCO1B1 gene, scientists aim to better understand why some individuals experience different responses to standard cholesterol-lowering therapies compared to others.
Research and Clinical Associations
Scientific research into SLCO1B1 has primarily focused on its impact on statin-induced myopathy. Large-scale genome-wide association studies have identified that certain variants in this gene are strongly linked to an increased risk of muscle pain or weakness in patients taking high doses of simvastatin. While rs4149056 is the most frequently cited variant in this context, rs4148211 is often included in genetic studies to determine if it contributes to the overall risk profile. The evidence for rs4148211 specifically is considered moderate, as it is often found in linkage disequilibrium with other functional variants, meaning it is inherited alongside them. It is crucial to note that genetic markers are only one piece of the puzzle; other factors such as age, sex, diet, and concurrent use of other medications also significantly influence how a person responds to statin therapy. Clinical guidelines emphasize that genetic testing should be interpreted by healthcare professionals who can weigh these findings against a patient's full medical history.
Navigating Genetic Information
Understanding your genetic profile can be an educational experience, but it is not a substitute for professional medical advice. If you are curious about how your genetics might influence your response to medication, the most important step is to have an open conversation with your doctor or pharmacist. They are equipped to interpret genetic data in the context of your specific health needs and can help you understand whether a particular medication is appropriate for you. You should never make changes to your prescribed treatment plan based on genetic information without consulting your healthcare provider first. While research into pharmacogenomics is rapidly advancing, it is still a developing field. Clinicians use a variety of tools, including blood tests and clinical assessments, to monitor your health and ensure that your treatment is safe and effective. Always prioritize the guidance of your medical team when making decisions about your health and medication management.
How common is this variant?
The rs4148211 variant is considered common, with its frequency varying across different global populations. Specific allele frequencies can be found in large-scale databases like gnomAD.
Frequently asked questions
Can this genetic test predict if I will have side effects from statins?
Genetic testing for SLCO1B1 provides information about your risk profile, but it cannot definitively predict whether you will experience side effects. Many factors, including your overall health and other medications, play a significant role in how you respond to statins.
Should I stop taking my statin if I have a variant in SLCO1B1?
No, you should never stop taking a prescribed medication without consulting your doctor. If you are concerned about your genetic results, discuss them with your healthcare provider to determine if your current treatment plan is still the best option for you.
Is rs4148211 the same as the *5 allele?
No, rs4148211 is a distinct SNP. The *5 allele is typically associated with the rs4149056 variant, which is the most well-studied marker for statin-induced myopathy in the SLCO1B1 gene.
Where can I find more information about my specific genotype?
You can look up your specific SNP in public databases like dbSNP or ClinVar for technical details. However, for clinical interpretation, always rely on a qualified healthcare professional who can review your results alongside your medical history.
Sources & further reading
Educational information only, last refreshed 9/30/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4148211?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLCO1B1
This missense variant (p.Pro155Thr) is associated with reduced OATP1B1 transporter function, which can lead to increased plasma concentrations of certain statins and higher risk of myopathy.
A regulatory variant in the SLCO1B1 gene influencing statin pharmacokinetics.
Defines the c.388A>G (p.Asn130Asp) variant, which is a component of the SLCO1B1*1B and *15 haplotypes, influencing hepatic statin uptake.
Non-synonymous coding polymorphism (p.Asn130Asp) defining the SLCO1B1*30 allele with modest alteration in hepatic statin uptake.
This variant (c.521T>C) is strongly associated with decreased function of the OATP1B1 transporter, significantly increasing the risk of statin-induced myopathy.
Known as SLCO1B1*1b (p.Asn130Asp), this variant alters hepatic transporter activity and modulates statin exposure and pharmacokinetic clearance.